Armellino Dc

CMC-544 (inotuzumab ozogamicin): A CD22-targeted immunoconjugate of calicheamicin

K. Khandke, Dylan W Evans, H. Ross, 2009 .

Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia

N. Damle, J. Dijoseph, D. Armellino, 2007, Leukemia.